A 2-year rat feeding study did not report any neoplastic endpoints at concentrations of DMP up to 4000 mg/kg bw/d. A one-year initiation/promotion study with dermal applications of 3000 mg/kg bw/d DMP in mice showed no evidence of carcinogenic initiation/promotion potential. A single mammalian cell transformation assay was negative. Overall, data were inadequate to determine the carcinogenic potential of DMP. The human and animal data were insufficient to assess adequately the effects of DMP on fertility. A single study reported effects on development from intraperitoneal injection of DMP in rats. In contrast, other studies (oral and dermal) reported no effects. Overall, data indicated that gestational exposure to DMP in rats or mice above doses likely to be maternally toxic are unlikely to have developmental consequences. The NOAEL for developmental effects in a rat oral feeding study was 3570 mg/kg bw/d (the highest dose tested).
A 2-year rat feeding study did not report any neoplastic endpoints at concentrations of DMP up to 4000 mg/kg bw/d. A one-year initiation/promotion study with dermal applications of 3000 mg/kg bw/d DMP in mice showed no evidence of carcinogenic initiation/promotion potential. A single mammalian cell transformation assay was negative. Overall, data were inadequate to determine the carcinogenic potential of DMP. The human and animal data were insufficient to assess adequately the effects of DMP on fertility. A single study reported effects on development from intraperitoneal injection of DMP in rats. In contrast, other studies (oral and dermal) reported no effects. Overall, data indicated that gestational exposure to DMP in rats or mice above doses likely to be maternally toxic are unlikely to have developmental consequences. The NOAEL for developmental effects in a rat oral feeding study was 3570 mg/kg bw/d (the highest dose tested).